awmsg logo

adalimumab (Humira®)

Reference No. 5

Publication date:

Appraisal information

adalimumab (Humira®) 40 mg solution for injection

Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: 02/12/2003
Submission Type: Full Submission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 01/03/2004

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA375) NICE GUIDANCE ISSUED JANUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. Adalimumab (Humira®) was appraised at the AWMSG December 2003 meeting, where it was decided that treatment within NHS Wales should be supported with restrictions. Restrictions identified included: • Adalimumab should only be available to physicians in secondary care specialising in rheumatology. • Adalimumab must be used in accordance with the British Society of Rheumatology guidelines for the use of anti-TNF agents. • Prescribers should be encouraged to report all suspected adverse reactions to adalimumab using the yellow card scheme. See AWMSG December 2003 meeting minutes for further information.
Final Appraisal Recommendation (FAR)